- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01399840
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
London, Regno Unito, SE5 9RS
- King's College Hospital
-
London, Regno Unito, NW1 2BU
- University College London
-
Manchester, Regno Unito, M20 4BX
- The Christie NHS Foundation
-
Newcastle upon Tyne, Regno Unito, NE1 7RU
- University of Newcastle Upon Tyne, NHS Foundation Trust
-
-
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Indiana University Simon Cancer Center
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109-1023
- Seattle Cancer Care Alliance
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53715
- University of Wisconsin
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- 18 years of age or older.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Arm 1 AML/MDS: Must have available tissue
- Arm 2 CLL/MCL: Must have available tissue
Have adequate organ function as defined below:
- Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN);
- Total serum bilirubin ≤ 1.5 X ULN;
- Able to take oral medications
- Recovered from acute toxicity of prior treatment
- Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
- If sexually active, must be willing to use an acceptable method of contraception during therapy and for 30 days after the last dose of BMN 673.
- If female of childbearing potential, must have a negative serum pregnancy test at screening and be willing to have additional pregnancy tests during the study.
- Willing and able to comply with all study procedures.
Exclusion Criteria:
- Acute promyelocytic leukemia, APL [AML with t(15;17)(q22;q12), PML-RARA and variants].
Disease-specific exclusion criteria:
a. AML: i. Marrow cellularity < 25% ii. Circulating blasts > 50,000/mm3 b. MCL and CLL: i. Platelet count < 50,000/mm3 ii. Neutrophil count < 1000/mm3
- Autologous bone marrow transplant < 6 months before Cycle 1 Day 1
- Prior allogeneic bone marrow transplant < 6 months before Cycle 1 Day 1 and/or with the presence of graft versus host disease (GVHD)
Prior treatment:
- AML: anti-leukemia treatment within 14 days before Cycle 1 Day 1; hydroxyurea treatment within 7 days before Cycle 1 Day 1.
- CLL, MCL or MDS: anti-lymphoma/leukemia treatment within 28 days before Cycle 1 Day 1;
- CLL/MCL patients who have received transfusion, hematopoietic growth factors within 7 days before Cycle 1 Day 1.
- Symptomatic central nervous system (CNS) involvement.
- Known to have human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV).
- Major surgery within 28 days before Cycle 1, Day 1.
- Active peptic ulcer disease.
- Active gastrointestinal tract disease with malabsorption syndrome.
- Requirement for IV alimentation.
- Prior surgical procedures affecting absorption.
- Uncontrolled inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
- Myocardial infarction within 6 months before Cycle 1 Day 1, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication.
- Breastfeeding at screening or planning to become pregnant (self or partner) at any time during study participation.
- Use of any investigational product or investigational medical device within 28 days before Cycle 1, Day 1.
Concurrent disease or condition that would interfere with study participation or safety, such as:
- CLL/MCL patients with active, clinically significant infection requiring the use of parenteral anti-microbial agents, or grade > 2 infection by NCI CTCAE (v4.03) within 14 days before Cycle 1, Day 1(AML/MDS patients with controlled infection are eligible for the study with no specific time requirement prior to Cycle 1, Day 1);
- Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders;
- Non-healing wound, ulcer, or bone fracture.
- Patients who have received prior treatment with a PARP inhibitor are not eligible for Part 2 of the study (expansion), but are eligible for Part 1 (dose escalation) of the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Arm 1: BMN 673
Arm 1 will enroll patients with either AML or MDS
|
Oral capsule with multiple dosage forms given once daily
|
|
Sperimentale: Arm 2: BMN 673
Arm 2 will enroll patients with either CLL or MCL
|
Oral capsule with multiple dosage forms given once daily
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
The primary outcome of this study is to determine the MTD of daily oral BMN 673 in patients with AML and MDS (Arm 1) and patients with CLL and MCL (Arm 2).
Lasso di tempo: Assessed after each visit until completion (Estimated duration is 12-18 months)
|
Assessed after each visit until completion (Estimated duration is 12-18 months)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with adverse events
Lasso di tempo: Assessed after each visit until completion of the study (Estimated duration is 24-30 months)
|
Assessed after each visit until completion of the study (Estimated duration is 24-30 months)
|
|
|
Determine the pharmacokinetic (PK) profile of BMN 673
Lasso di tempo: Assessed at each visit in cycle 1 - 5 (Estimated duration is 24 months)
|
Sample collection times vary per visit.
PK parameters that will be evaluated include: maximum concentration (Cmax), minimum concentration (Cmin), time to maximum plasma concentration (Tmax), area under the curve from 0 to last quantifiable sampling point postdose (AUC0-inf), area under the curve extrapolated to infinity (AUC0-last), half life (t1/2), systemic clearance (CL/f) and volume of ditribution (VZ/f)
|
Assessed at each visit in cycle 1 - 5 (Estimated duration is 24 months)
|
|
Determine the Recommended Phase 2 Dose (RP2D) of oral daily BMN 673
Lasso di tempo: Assessed after each visit until completion of the study (Estimated duration is 24-30 months)
|
Assessed after each visit until completion of the study (Estimated duration is 24-30 months)
|
|
|
Assess preliminary efficacy of BMN 673 by evaluating per response publications
Lasso di tempo: Assessed approximately every 4-12 weeks (Estimated duration is 24-30 months)
|
Assessed approximately every 4-12 weeks (Estimated duration is 24-30 months)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie
- Malattie linfoproliferative
- Malattie linfatiche
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Neoplasie per sede
- Malattie del midollo osseo
- Malattie ematologiche
- Leucemia, linfoide
- Leucemia, cellule B
- Linfoma
- Sindromi mielodisplastiche
- Neoplasie ematologiche
- Leucemia
- Linfoma, cellule del mantello
- Leucemia, linfocitica, cronica, cellule B
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori della poli(ADP-ribosio) polimerasi
- Talazoparib
Altri numeri di identificazione dello studio
- PRP-002
- 2010-023964-42 (Numero EudraCT)
- C3441022 (Altro identificatore: Alias Study Number)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .